Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

BRIEF- Valeant provides update regarding government inquiries

Published 2015-10-14, 09:25 p/m
© Reuters.  BRIEF- Valeant provides update regarding government inquiries
BHC
-

Oct 14 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) VRX.TO :
* Provides update regarding government inquiries
* Responds to a letter from Senator Claire McCaskill concerning company's
products Nitropress and Isuprel
* Response addressed history of Nitropress, Isuprel,reimbursement process for
hospital procedures,among other topics
* Says recently received a subpoena from the U.S. attorney's office for
district of Massachusetts
* Says also recieved subpoena from the U.S. attorney's office for the southern
district of New York
* Says company is reviewing the subpoenas and intends to cooperate with the
investigations
* Says is reviewing the subpoenas and intends to cooperate with the
investigations
* Says most materials requested by subpoenas relate to documents with respect
to patient assistance programs
* Suboenas also include requests relating to financial support provided by the
company for patients
* Source text for Eikon ID:nPn9XPtbC
* Further company coverage VRX.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.